Global Endogenous Peptide Substances Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our LPI (LP Information) latest study, the global Endogenous Peptide Substances market size was valued at US$ million in 2022. With growing demand in downstream market, the Endogenous Peptide Substances is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global Endogenous Peptide Substances market. Endogenous Peptide Substances are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Endogenous Peptide Substances. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Endogenous Peptide Substances market.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
Key Features:
The report on Endogenous Peptide Substances market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Endogenous Peptide Substances market. It may include historical data, market segmentation by Type (e.g., Neuropeptides, Hormones), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Endogenous Peptide Substances market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Endogenous Peptide Substances market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Endogenous Peptide Substances industry. This include advancements in Endogenous Peptide Substances technology, Endogenous Peptide Substances new entrants, Endogenous Peptide Substances new investment, and other innovations that are shaping the future of Endogenous Peptide Substances.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Endogenous Peptide Substances market. It includes factors influencing customer ' purchasing decisions, preferences for Endogenous Peptide Substances product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Endogenous Peptide Substances market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Endogenous Peptide Substances market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Endogenous Peptide Substances market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Endogenous Peptide Substances industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Endogenous Peptide Substances market.
Market Segmentation:
Endogenous Peptide Substances market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our LPI (LP Information) latest study, the global Endogenous Peptide Substances market size was valued at US$ million in 2022. With growing demand in downstream market, the Endogenous Peptide Substances is forecast to a readjusted size of US$ million by 2029 with a CAGR of % during review period.
The research report highlights the growth potential of the global Endogenous Peptide Substances market. Endogenous Peptide Substances are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Endogenous Peptide Substances. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Endogenous Peptide Substances market.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people's demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
Key Features:
The report on Endogenous Peptide Substances market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Endogenous Peptide Substances market. It may include historical data, market segmentation by Type (e.g., Neuropeptides, Hormones), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Endogenous Peptide Substances market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Endogenous Peptide Substances market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Endogenous Peptide Substances industry. This include advancements in Endogenous Peptide Substances technology, Endogenous Peptide Substances new entrants, Endogenous Peptide Substances new investment, and other innovations that are shaping the future of Endogenous Peptide Substances.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Endogenous Peptide Substances market. It includes factors influencing customer ' purchasing decisions, preferences for Endogenous Peptide Substances product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Endogenous Peptide Substances market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Endogenous Peptide Substances market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Endogenous Peptide Substances market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Endogenous Peptide Substances industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Endogenous Peptide Substances market.
Market Segmentation:
Endogenous Peptide Substances market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Neuropeptides
- Hormones
- Cytokines
- Peptide Hormones
- Bioactive Peptides
- Research
- Medicine
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Assertio Therapeutics Inc.
- Cipher Pharmaceuticals Inc.
- Endo International Plc
- Biosynth Carbosynth
- Lannett Co. Inc.
- Pfizer
- Johnson & Johnson
- Peptide Institute
- Abbexa
- Phoenix Pharmaceuticals
- Creative Peptides
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Endogenous Peptide Substances Market Size 2018-2029
2.1.2 Endogenous Peptide Substances Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Endogenous Peptide Substances Segment by Type
2.2.1 Neuropeptides
2.2.2 Hormones
2.2.3 Cytokines
2.2.4 Peptide Hormones
2.2.5 Bioactive Peptides
2.3 Endogenous Peptide Substances Market Size by Type
2.3.1 Endogenous Peptide Substances Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
2.4 Endogenous Peptide Substances Segment by Application
2.4.1 Research
2.4.2 Medicine
2.4.3 Others
2.5 Endogenous Peptide Substances Market Size by Application
2.5.1 Endogenous Peptide Substances Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
3 ENDOGENOUS PEPTIDE SUBSTANCES MARKET SIZE BY PLAYER
3.1 Endogenous Peptide Substances Market Size Market Share by Players
3.1.1 Global Endogenous Peptide Substances Revenue by Players (2018-2023)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Players (2018-2023)
3.2 Global Endogenous Peptide Substances Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ENDOGENOUS PEPTIDE SUBSTANCES BY REGIONS
4.1 Endogenous Peptide Substances Market Size by Regions (2018-2023)
4.2 Americas Endogenous Peptide Substances Market Size Growth (2018-2023)
4.3 APAC Endogenous Peptide Substances Market Size Growth (2018-2023)
4.4 Europe Endogenous Peptide Substances Market Size Growth (2018-2023)
4.5 Middle East & Africa Endogenous Peptide Substances Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Endogenous Peptide Substances Market Size by Country (2018-2023)
5.2 Americas Endogenous Peptide Substances Market Size by Type (2018-2023)
5.3 Americas Endogenous Peptide Substances Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Endogenous Peptide Substances Market Size by Region (2018-2023)
6.2 APAC Endogenous Peptide Substances Market Size by Type (2018-2023)
6.3 APAC Endogenous Peptide Substances Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Endogenous Peptide Substances by Country (2018-2023)
7.2 Europe Endogenous Peptide Substances Market Size by Type (2018-2023)
7.3 Europe Endogenous Peptide Substances Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Endogenous Peptide Substances by Region (2018-2023)
8.2 Middle East & Africa Endogenous Peptide Substances Market Size by Type (2018-2023)
8.3 Middle East & Africa Endogenous Peptide Substances Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ENDOGENOUS PEPTIDE SUBSTANCES MARKET FORECAST
10.1 Global Endogenous Peptide Substances Forecast by Regions (2024-2029)
10.1.1 Global Endogenous Peptide Substances Forecast by Regions (2024-2029)
10.1.2 Americas Endogenous Peptide Substances Forecast
10.1.3 APAC Endogenous Peptide Substances Forecast
10.1.4 Europe Endogenous Peptide Substances Forecast
10.1.5 Middle East & Africa Endogenous Peptide Substances Forecast
10.2 Americas Endogenous Peptide Substances Forecast by Country (2024-2029)
10.2.1 United States Endogenous Peptide Substances Market Forecast
10.2.2 Canada Endogenous Peptide Substances Market Forecast
10.2.3 Mexico Endogenous Peptide Substances Market Forecast
10.2.4 Brazil Endogenous Peptide Substances Market Forecast
10.3 APAC Endogenous Peptide Substances Forecast by Region (2024-2029)
10.3.1 China Endogenous Peptide Substances Market Forecast
10.3.2 Japan Endogenous Peptide Substances Market Forecast
10.3.3 Korea Endogenous Peptide Substances Market Forecast
10.3.4 Southeast Asia Endogenous Peptide Substances Market Forecast
10.3.5 India Endogenous Peptide Substances Market Forecast
10.3.6 Australia Endogenous Peptide Substances Market Forecast
10.4 Europe Endogenous Peptide Substances Forecast by Country (2024-2029)
10.4.1 Germany Endogenous Peptide Substances Market Forecast
10.4.2 France Endogenous Peptide Substances Market Forecast
10.4.3 UK Endogenous Peptide Substances Market Forecast
10.4.4 Italy Endogenous Peptide Substances Market Forecast
10.4.5 Russia Endogenous Peptide Substances Market Forecast
10.5 Middle East & Africa Endogenous Peptide Substances Forecast by Region (2024-2029)
10.5.1 Egypt Endogenous Peptide Substances Market Forecast
10.5.2 South Africa Endogenous Peptide Substances Market Forecast
10.5.3 Israel Endogenous Peptide Substances Market Forecast
10.5.4 Turkey Endogenous Peptide Substances Market Forecast
10.5.5 GCC Countries Endogenous Peptide Substances Market Forecast
10.6 Global Endogenous Peptide Substances Forecast by Type (2024-2029)
10.7 Global Endogenous Peptide Substances Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Information
11.1.2 Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Assertio Therapeutics Inc. Main Business Overview
11.1.5 Assertio Therapeutics Inc. Latest Developments
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Information
11.2.2 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Cipher Pharmaceuticals Inc. Main Business Overview
11.2.5 Cipher Pharmaceuticals Inc. Latest Developments
11.3 Endo International Plc
11.3.1 Endo International Plc Company Information
11.3.2 Endo International Plc Endogenous Peptide Substances Product Offered
11.3.3 Endo International Plc Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Endo International Plc Main Business Overview
11.3.5 Endo International Plc Latest Developments
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Information
11.4.2 Biosynth Carbosynth Endogenous Peptide Substances Product Offered
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Biosynth Carbosynth Main Business Overview
11.4.5 Biosynth Carbosynth Latest Developments
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Information
11.5.2 Lannett Co. Inc. Endogenous Peptide Substances Product Offered
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Lannett Co. Inc. Main Business Overview
11.5.5 Lannett Co. Inc. Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Endogenous Peptide Substances Product Offered
11.6.3 Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Endogenous Peptide Substances Product Offered
11.7.3 Johnson & Johnson Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Johnson & Johnson Main Business Overview
11.7.5 Johnson & Johnson Latest Developments
11.8 Peptide Institute
11.8.1 Peptide Institute Company Information
11.8.2 Peptide Institute Endogenous Peptide Substances Product Offered
11.8.3 Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Peptide Institute Main Business Overview
11.8.5 Peptide Institute Latest Developments
11.9 Abbexa
11.9.1 Abbexa Company Information
11.9.2 Abbexa Endogenous Peptide Substances Product Offered
11.9.3 Abbexa Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Abbexa Main Business Overview
11.9.5 Abbexa Latest Developments
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Information
11.10.2 Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Phoenix Pharmaceuticals Main Business Overview
11.10.5 Phoenix Pharmaceuticals Latest Developments
11.11 Creative Peptides
11.11.1 Creative Peptides Company Information
11.11.2 Creative Peptides Endogenous Peptide Substances Product Offered
11.11.3 Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Creative Peptides Main Business Overview
11.11.5 Creative Peptides Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Endogenous Peptide Substances Market Size 2018-2029
2.1.2 Endogenous Peptide Substances Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Endogenous Peptide Substances Segment by Type
2.2.1 Neuropeptides
2.2.2 Hormones
2.2.3 Cytokines
2.2.4 Peptide Hormones
2.2.5 Bioactive Peptides
2.3 Endogenous Peptide Substances Market Size by Type
2.3.1 Endogenous Peptide Substances Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
2.4 Endogenous Peptide Substances Segment by Application
2.4.1 Research
2.4.2 Medicine
2.4.3 Others
2.5 Endogenous Peptide Substances Market Size by Application
2.5.1 Endogenous Peptide Substances Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
3 ENDOGENOUS PEPTIDE SUBSTANCES MARKET SIZE BY PLAYER
3.1 Endogenous Peptide Substances Market Size Market Share by Players
3.1.1 Global Endogenous Peptide Substances Revenue by Players (2018-2023)
3.1.2 Global Endogenous Peptide Substances Revenue Market Share by Players (2018-2023)
3.2 Global Endogenous Peptide Substances Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 ENDOGENOUS PEPTIDE SUBSTANCES BY REGIONS
4.1 Endogenous Peptide Substances Market Size by Regions (2018-2023)
4.2 Americas Endogenous Peptide Substances Market Size Growth (2018-2023)
4.3 APAC Endogenous Peptide Substances Market Size Growth (2018-2023)
4.4 Europe Endogenous Peptide Substances Market Size Growth (2018-2023)
4.5 Middle East & Africa Endogenous Peptide Substances Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Endogenous Peptide Substances Market Size by Country (2018-2023)
5.2 Americas Endogenous Peptide Substances Market Size by Type (2018-2023)
5.3 Americas Endogenous Peptide Substances Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Endogenous Peptide Substances Market Size by Region (2018-2023)
6.2 APAC Endogenous Peptide Substances Market Size by Type (2018-2023)
6.3 APAC Endogenous Peptide Substances Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Endogenous Peptide Substances by Country (2018-2023)
7.2 Europe Endogenous Peptide Substances Market Size by Type (2018-2023)
7.3 Europe Endogenous Peptide Substances Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Endogenous Peptide Substances by Region (2018-2023)
8.2 Middle East & Africa Endogenous Peptide Substances Market Size by Type (2018-2023)
8.3 Middle East & Africa Endogenous Peptide Substances Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL ENDOGENOUS PEPTIDE SUBSTANCES MARKET FORECAST
10.1 Global Endogenous Peptide Substances Forecast by Regions (2024-2029)
10.1.1 Global Endogenous Peptide Substances Forecast by Regions (2024-2029)
10.1.2 Americas Endogenous Peptide Substances Forecast
10.1.3 APAC Endogenous Peptide Substances Forecast
10.1.4 Europe Endogenous Peptide Substances Forecast
10.1.5 Middle East & Africa Endogenous Peptide Substances Forecast
10.2 Americas Endogenous Peptide Substances Forecast by Country (2024-2029)
10.2.1 United States Endogenous Peptide Substances Market Forecast
10.2.2 Canada Endogenous Peptide Substances Market Forecast
10.2.3 Mexico Endogenous Peptide Substances Market Forecast
10.2.4 Brazil Endogenous Peptide Substances Market Forecast
10.3 APAC Endogenous Peptide Substances Forecast by Region (2024-2029)
10.3.1 China Endogenous Peptide Substances Market Forecast
10.3.2 Japan Endogenous Peptide Substances Market Forecast
10.3.3 Korea Endogenous Peptide Substances Market Forecast
10.3.4 Southeast Asia Endogenous Peptide Substances Market Forecast
10.3.5 India Endogenous Peptide Substances Market Forecast
10.3.6 Australia Endogenous Peptide Substances Market Forecast
10.4 Europe Endogenous Peptide Substances Forecast by Country (2024-2029)
10.4.1 Germany Endogenous Peptide Substances Market Forecast
10.4.2 France Endogenous Peptide Substances Market Forecast
10.4.3 UK Endogenous Peptide Substances Market Forecast
10.4.4 Italy Endogenous Peptide Substances Market Forecast
10.4.5 Russia Endogenous Peptide Substances Market Forecast
10.5 Middle East & Africa Endogenous Peptide Substances Forecast by Region (2024-2029)
10.5.1 Egypt Endogenous Peptide Substances Market Forecast
10.5.2 South Africa Endogenous Peptide Substances Market Forecast
10.5.3 Israel Endogenous Peptide Substances Market Forecast
10.5.4 Turkey Endogenous Peptide Substances Market Forecast
10.5.5 GCC Countries Endogenous Peptide Substances Market Forecast
10.6 Global Endogenous Peptide Substances Forecast by Type (2024-2029)
10.7 Global Endogenous Peptide Substances Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Assertio Therapeutics Inc.
11.1.1 Assertio Therapeutics Inc. Company Information
11.1.2 Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
11.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Assertio Therapeutics Inc. Main Business Overview
11.1.5 Assertio Therapeutics Inc. Latest Developments
11.2 Cipher Pharmaceuticals Inc.
11.2.1 Cipher Pharmaceuticals Inc. Company Information
11.2.2 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
11.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Cipher Pharmaceuticals Inc. Main Business Overview
11.2.5 Cipher Pharmaceuticals Inc. Latest Developments
11.3 Endo International Plc
11.3.1 Endo International Plc Company Information
11.3.2 Endo International Plc Endogenous Peptide Substances Product Offered
11.3.3 Endo International Plc Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Endo International Plc Main Business Overview
11.3.5 Endo International Plc Latest Developments
11.4 Biosynth Carbosynth
11.4.1 Biosynth Carbosynth Company Information
11.4.2 Biosynth Carbosynth Endogenous Peptide Substances Product Offered
11.4.3 Biosynth Carbosynth Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Biosynth Carbosynth Main Business Overview
11.4.5 Biosynth Carbosynth Latest Developments
11.5 Lannett Co. Inc.
11.5.1 Lannett Co. Inc. Company Information
11.5.2 Lannett Co. Inc. Endogenous Peptide Substances Product Offered
11.5.3 Lannett Co. Inc. Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Lannett Co. Inc. Main Business Overview
11.5.5 Lannett Co. Inc. Latest Developments
11.6 Pfizer
11.6.1 Pfizer Company Information
11.6.2 Pfizer Endogenous Peptide Substances Product Offered
11.6.3 Pfizer Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Pfizer Main Business Overview
11.6.5 Pfizer Latest Developments
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Information
11.7.2 Johnson & Johnson Endogenous Peptide Substances Product Offered
11.7.3 Johnson & Johnson Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Johnson & Johnson Main Business Overview
11.7.5 Johnson & Johnson Latest Developments
11.8 Peptide Institute
11.8.1 Peptide Institute Company Information
11.8.2 Peptide Institute Endogenous Peptide Substances Product Offered
11.8.3 Peptide Institute Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Peptide Institute Main Business Overview
11.8.5 Peptide Institute Latest Developments
11.9 Abbexa
11.9.1 Abbexa Company Information
11.9.2 Abbexa Endogenous Peptide Substances Product Offered
11.9.3 Abbexa Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Abbexa Main Business Overview
11.9.5 Abbexa Latest Developments
11.10 Phoenix Pharmaceuticals
11.10.1 Phoenix Pharmaceuticals Company Information
11.10.2 Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
11.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Phoenix Pharmaceuticals Main Business Overview
11.10.5 Phoenix Pharmaceuticals Latest Developments
11.11 Creative Peptides
11.11.1 Creative Peptides Company Information
11.11.2 Creative Peptides Endogenous Peptide Substances Product Offered
11.11.3 Creative Peptides Endogenous Peptide Substances Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Creative Peptides Main Business Overview
11.11.5 Creative Peptides Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Endogenous Peptide Substances Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Neuropeptides
Table 3. Major Players of Hormones
Table 4. Major Players of Cytokines
Table 5. Major Players of Peptide Hormones
Table 6. Major Players of Bioactive Peptides
Table 7. Endogenous Peptide Substances Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 9. Global Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 10. Endogenous Peptide Substances Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 11. Global Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 12. Global Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 13. Global Endogenous Peptide Substances Revenue by Players (2018-2023) & ($ Millions)
Table 14. Global Endogenous Peptide Substances Revenue Market Share by Player (2018-2023)
Table 15. Endogenous Peptide Substances Key Players Head office and Products Offered
Table 16. Endogenous Peptide Substances Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Endogenous Peptide Substances Market Size by Regions 2018-2023 & ($ Millions)
Table 20. Global Endogenous Peptide Substances Market Size Market Share by Regions (2018-2023)
Table 21. Global Endogenous Peptide Substances Revenue by Country/Region (2018-2023) & ($ millions)
Table 22. Global Endogenous Peptide Substances Revenue Market Share by Country/Region (2018-2023)
Table 23. Americas Endogenous Peptide Substances Market Size by Country (2018-2023) & ($ Millions)
Table 24. Americas Endogenous Peptide Substances Market Size Market Share by Country (2018-2023)
Table 25. Americas Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 26. Americas Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 27. Americas Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 28. Americas Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 29. APAC Endogenous Peptide Substances Market Size by Region (2018-2023) & ($ Millions)
Table 30. APAC Endogenous Peptide Substances Market Size Market Share by Region (2018-2023)
Table 31. APAC Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 32. APAC Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 33. APAC Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 34. APAC Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 35. Europe Endogenous Peptide Substances Market Size by Country (2018-2023) & ($ Millions)
Table 36. Europe Endogenous Peptide Substances Market Size Market Share by Country (2018-2023)
Table 37. Europe Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 38. Europe Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 39. Europe Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 40. Europe Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 41. Middle East & Africa Endogenous Peptide Substances Market Size by Region (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Region (2018-2023)
Table 43. Middle East & Africa Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 45. Middle East & Africa Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 47. Key Market Drivers & Growth Opportunities of Endogenous Peptide Substances
Table 48. Key Market Challenges & Risks of Endogenous Peptide Substances
Table 49. Key Industry Trends of Endogenous Peptide Substances
Table 50. Global Endogenous Peptide Substances Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 51. Global Endogenous Peptide Substances Market Size Market Share Forecast by Regions (2024-2029)
Table 52. Global Endogenous Peptide Substances Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 53. Global Endogenous Peptide Substances Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 54. Assertio Therapeutics Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 55. Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
Table 56. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 57. Assertio Therapeutics Inc. Main Business
Table 58. Assertio Therapeutics Inc. Latest Developments
Table 59. Cipher Pharmaceuticals Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 60. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
Table 61. Cipher Pharmaceuticals Inc. Main Business
Table 62. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 63. Cipher Pharmaceuticals Inc. Latest Developments
Table 64. Endo International Plc Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 65. Endo International Plc Endogenous Peptide Substances Product Offered
Table 66. Endo International Plc Main Business
Table 67. Endo International Plc Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 68. Endo International Plc Latest Developments
Table 69. Biosynth Carbosynth Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 70. Biosynth Carbosynth Endogenous Peptide Substances Product Offered
Table 71. Biosynth Carbosynth Main Business
Table 72. Biosynth Carbosynth Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 73. Biosynth Carbosynth Latest Developments
Table 74. Lannett Co. Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 75. Lannett Co. Inc. Endogenous Peptide Substances Product Offered
Table 76. Lannett Co. Inc. Main Business
Table 77. Lannett Co. Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 78. Lannett Co. Inc. Latest Developments
Table 79. Pfizer Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 80. Pfizer Endogenous Peptide Substances Product Offered
Table 81. Pfizer Main Business
Table 82. Pfizer Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 83. Pfizer Latest Developments
Table 84. Johnson & Johnson Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 85. Johnson & Johnson Endogenous Peptide Substances Product Offered
Table 86. Johnson & Johnson Main Business
Table 87. Johnson & Johnson Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 88. Johnson & Johnson Latest Developments
Table 89. Peptide Institute Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 90. Peptide Institute Endogenous Peptide Substances Product Offered
Table 91. Peptide Institute Main Business
Table 92. Peptide Institute Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 93. Peptide Institute Latest Developments
Table 94. Abbexa Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 95. Abbexa Endogenous Peptide Substances Product Offered
Table 96. Abbexa Main Business
Table 97. Abbexa Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 98. Abbexa Latest Developments
Table 99. Phoenix Pharmaceuticals Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 100. Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
Table 101. Phoenix Pharmaceuticals Main Business
Table 102. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 103. Phoenix Pharmaceuticals Latest Developments
Table 104. Creative Peptides Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 105. Creative Peptides Endogenous Peptide Substances Product Offered
Table 106. Creative Peptides Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 107. Creative Peptides Main Business
Table 108. Creative Peptides Latest Developments
Table 1. Endogenous Peptide Substances Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Neuropeptides
Table 3. Major Players of Hormones
Table 4. Major Players of Cytokines
Table 5. Major Players of Peptide Hormones
Table 6. Major Players of Bioactive Peptides
Table 7. Endogenous Peptide Substances Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 9. Global Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 10. Endogenous Peptide Substances Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 11. Global Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 12. Global Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 13. Global Endogenous Peptide Substances Revenue by Players (2018-2023) & ($ Millions)
Table 14. Global Endogenous Peptide Substances Revenue Market Share by Player (2018-2023)
Table 15. Endogenous Peptide Substances Key Players Head office and Products Offered
Table 16. Endogenous Peptide Substances Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 17. New Products and Potential Entrants
Table 18. Mergers & Acquisitions, Expansion
Table 19. Global Endogenous Peptide Substances Market Size by Regions 2018-2023 & ($ Millions)
Table 20. Global Endogenous Peptide Substances Market Size Market Share by Regions (2018-2023)
Table 21. Global Endogenous Peptide Substances Revenue by Country/Region (2018-2023) & ($ millions)
Table 22. Global Endogenous Peptide Substances Revenue Market Share by Country/Region (2018-2023)
Table 23. Americas Endogenous Peptide Substances Market Size by Country (2018-2023) & ($ Millions)
Table 24. Americas Endogenous Peptide Substances Market Size Market Share by Country (2018-2023)
Table 25. Americas Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 26. Americas Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 27. Americas Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 28. Americas Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 29. APAC Endogenous Peptide Substances Market Size by Region (2018-2023) & ($ Millions)
Table 30. APAC Endogenous Peptide Substances Market Size Market Share by Region (2018-2023)
Table 31. APAC Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 32. APAC Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 33. APAC Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 34. APAC Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 35. Europe Endogenous Peptide Substances Market Size by Country (2018-2023) & ($ Millions)
Table 36. Europe Endogenous Peptide Substances Market Size Market Share by Country (2018-2023)
Table 37. Europe Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 38. Europe Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 39. Europe Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 40. Europe Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 41. Middle East & Africa Endogenous Peptide Substances Market Size by Region (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Region (2018-2023)
Table 43. Middle East & Africa Endogenous Peptide Substances Market Size by Type (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Table 45. Middle East & Africa Endogenous Peptide Substances Market Size by Application (2018-2023) & ($ Millions)
Table 46. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Table 47. Key Market Drivers & Growth Opportunities of Endogenous Peptide Substances
Table 48. Key Market Challenges & Risks of Endogenous Peptide Substances
Table 49. Key Industry Trends of Endogenous Peptide Substances
Table 50. Global Endogenous Peptide Substances Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 51. Global Endogenous Peptide Substances Market Size Market Share Forecast by Regions (2024-2029)
Table 52. Global Endogenous Peptide Substances Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 53. Global Endogenous Peptide Substances Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 54. Assertio Therapeutics Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 55. Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offered
Table 56. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 57. Assertio Therapeutics Inc. Main Business
Table 58. Assertio Therapeutics Inc. Latest Developments
Table 59. Cipher Pharmaceuticals Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 60. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offered
Table 61. Cipher Pharmaceuticals Inc. Main Business
Table 62. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 63. Cipher Pharmaceuticals Inc. Latest Developments
Table 64. Endo International Plc Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 65. Endo International Plc Endogenous Peptide Substances Product Offered
Table 66. Endo International Plc Main Business
Table 67. Endo International Plc Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 68. Endo International Plc Latest Developments
Table 69. Biosynth Carbosynth Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 70. Biosynth Carbosynth Endogenous Peptide Substances Product Offered
Table 71. Biosynth Carbosynth Main Business
Table 72. Biosynth Carbosynth Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 73. Biosynth Carbosynth Latest Developments
Table 74. Lannett Co. Inc. Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 75. Lannett Co. Inc. Endogenous Peptide Substances Product Offered
Table 76. Lannett Co. Inc. Main Business
Table 77. Lannett Co. Inc. Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 78. Lannett Co. Inc. Latest Developments
Table 79. Pfizer Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 80. Pfizer Endogenous Peptide Substances Product Offered
Table 81. Pfizer Main Business
Table 82. Pfizer Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 83. Pfizer Latest Developments
Table 84. Johnson & Johnson Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 85. Johnson & Johnson Endogenous Peptide Substances Product Offered
Table 86. Johnson & Johnson Main Business
Table 87. Johnson & Johnson Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 88. Johnson & Johnson Latest Developments
Table 89. Peptide Institute Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 90. Peptide Institute Endogenous Peptide Substances Product Offered
Table 91. Peptide Institute Main Business
Table 92. Peptide Institute Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 93. Peptide Institute Latest Developments
Table 94. Abbexa Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 95. Abbexa Endogenous Peptide Substances Product Offered
Table 96. Abbexa Main Business
Table 97. Abbexa Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 98. Abbexa Latest Developments
Table 99. Phoenix Pharmaceuticals Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 100. Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offered
Table 101. Phoenix Pharmaceuticals Main Business
Table 102. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 103. Phoenix Pharmaceuticals Latest Developments
Table 104. Creative Peptides Details, Company Type, Endogenous Peptide Substances Area Served and Its Competitors
Table 105. Creative Peptides Endogenous Peptide Substances Product Offered
Table 106. Creative Peptides Endogenous Peptide Substances Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 107. Creative Peptides Main Business
Table 108. Creative Peptides Latest Developments
LIST OF FIGURES
Figure 1. Endogenous Peptide Substances Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Endogenous Peptide Substances Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Endogenous Peptide Substances Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Endogenous Peptide Substances Sales Market Share by Country/Region (2022)
Figure 8. Endogenous Peptide Substances Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Endogenous Peptide Substances Market Size Market Share by Type in 2022
Figure 10. Endogenous Peptide Substances in Research
Figure 11. Global Endogenous Peptide Substances Market: Research (2018-2023) & ($ Millions)
Figure 12. Endogenous Peptide Substances in Medicine
Figure 13. Global Endogenous Peptide Substances Market: Medicine (2018-2023) & ($ Millions)
Figure 14. Endogenous Peptide Substances in Others
Figure 15. Global Endogenous Peptide Substances Market: Others (2018-2023) & ($ Millions)
Figure 16. Global Endogenous Peptide Substances Market Size Market Share by Application in 2022
Figure 17. Global Endogenous Peptide Substances Revenue Market Share by Player in 2022
Figure 18. Global Endogenous Peptide Substances Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 20. APAC Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 21. Europe Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 23. Americas Endogenous Peptide Substances Value Market Share by Country in 2022
Figure 24. United States Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Endogenous Peptide Substances Market Size Market Share by Region in 2022
Figure 29. APAC Endogenous Peptide Substances Market Size Market Share by Type in 2022
Figure 30. APAC Endogenous Peptide Substances Market Size Market Share by Application in 2022
Figure 31. China Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Endogenous Peptide Substances Market Size Market Share by Country in 2022
Figure 38. Europe Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Figure 39. Europe Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Figure 40. Germany Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 54. APAC Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 55. Europe Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 57. United States Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 58. Canada Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 61. China Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 62. Japan Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 63. Korea Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 65. India Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 66. Australia Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 67. Germany Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 68. France Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 69. UK Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 70. Italy Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 71. Russia Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 72. Spain Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 75. Israel Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 78. Global Endogenous Peptide Substances Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Endogenous Peptide Substances Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Endogenous Peptide Substances Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Endogenous Peptide Substances Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Endogenous Peptide Substances Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Endogenous Peptide Substances Sales Market Share by Country/Region (2022)
Figure 8. Endogenous Peptide Substances Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Endogenous Peptide Substances Market Size Market Share by Type in 2022
Figure 10. Endogenous Peptide Substances in Research
Figure 11. Global Endogenous Peptide Substances Market: Research (2018-2023) & ($ Millions)
Figure 12. Endogenous Peptide Substances in Medicine
Figure 13. Global Endogenous Peptide Substances Market: Medicine (2018-2023) & ($ Millions)
Figure 14. Endogenous Peptide Substances in Others
Figure 15. Global Endogenous Peptide Substances Market: Others (2018-2023) & ($ Millions)
Figure 16. Global Endogenous Peptide Substances Market Size Market Share by Application in 2022
Figure 17. Global Endogenous Peptide Substances Revenue Market Share by Player in 2022
Figure 18. Global Endogenous Peptide Substances Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 20. APAC Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 21. Europe Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Endogenous Peptide Substances Market Size 2018-2023 ($ Millions)
Figure 23. Americas Endogenous Peptide Substances Value Market Share by Country in 2022
Figure 24. United States Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Endogenous Peptide Substances Market Size Market Share by Region in 2022
Figure 29. APAC Endogenous Peptide Substances Market Size Market Share by Type in 2022
Figure 30. APAC Endogenous Peptide Substances Market Size Market Share by Application in 2022
Figure 31. China Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Endogenous Peptide Substances Market Size Market Share by Country in 2022
Figure 38. Europe Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Figure 39. Europe Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Figure 40. Germany Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Endogenous Peptide Substances Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Endogenous Peptide Substances Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 54. APAC Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 55. Europe Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 57. United States Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 58. Canada Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 61. China Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 62. Japan Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 63. Korea Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 65. India Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 66. Australia Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 67. Germany Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 68. France Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 69. UK Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 70. Italy Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 71. Russia Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 72. Spain Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 75. Israel Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Endogenous Peptide Substances Market Size 2024-2029 ($ Millions)
Figure 78. Global Endogenous Peptide Substances Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Endogenous Peptide Substances Market Size Market Share Forecast by Application (2024-2029)
